Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
Objective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into the National Immunization Program of Argentina, and to describe variables associated with...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Pan American Health Organization
2018-11-01
|
Series: | Revista Panamericana de Salud Pública |
Subjects: | |
Online Access: | http://iris.paho.org/xmlui/handle/123456789/49588 |
id |
doaj-3eeedd1bdc4a4b9b972a3b1f4d49dddf |
---|---|
record_format |
Article |
spelling |
doaj-3eeedd1bdc4a4b9b972a3b1f4d49dddf2020-11-24T21:51:18ZengPan American Health OrganizationRevista Panamericana de Salud Pública1020-49891680-53482018-11-01421810.26633/RPSP.2018.167e167Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impactRaúl O. Ruvinsky0Analía Rearte1Judit Kupervaser2Fernando Gentile3Adriana Haidar4Maria E. Cafure5Maria Elisa Tito6Federico Avaro7Cristina Cortiana8Hugo Cozzani9Omar Véliz10Sofia Fossati11Mabel Regueira12Carla Vizzotti13Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, ArgentinaDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, ArgentinaHospital Delicia Concepción Masvernat, Concordia, Entre Ríos, ArgentinaHospital de Niños Ricardo Gutiérrez, Buenos Aires, ArgentinaHospital Delicia Concepción Masvernat, Concordia, Entre Ríos, ArgentinaCentro Provincial de Salud Constitución, Concordia, Entre Ríos, ArgentinaHospital Delicia Concepción Masvernat, Concordia, Entre Ríos, ArgentinaHospital Felipe Heras, Concordia, Entre Ríos, ArgentinaHospital Ramón Carrillo, Concordia, Entre Ríos, ArgentinaHospital de Niños Ricardo Gutiérrez, Buenos Aires, ArgentinaBacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán,” Buenos Aires, ArgentinaBacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán,” Buenos Aires, ArgentinaBacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán,” Buenos Aires, ArgentinaDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, ArgentinaObjective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into the National Immunization Program of Argentina, and to describe variables associated with bacterial pneumonia and hospitalization. Methods. This was a prospective, population-based surveillance study of CAP incidence (ambulatory and hospitalized) among children less than 5 years of age in the Department of Concordia (Entre Rios, Argentina) from April 2014 – March 2016. The diagnosis of probable bacterial pneumonia (PBP) was determined following the standardized WHO protocol. Incidence during the post-vaccine introduction period was compared with the results from a previous study that used similar methodology for the pre-PCV13 introduction period from 2002 – 2005. Results. During the study period, 330 patients had a clinical diagnosis of CAP, of which 92 were PBP (6 with pleural effusion). S. pneumoniae was not isolated from any sample. No factors associated with PBP were found in multivariable analysis. The decrease in PBP and pleural effusion was significant in relation to the previous study: 63% (P < 0.0001) and 80.9% (P < 0.003), respectively. PCV13 uptake was 97.3% for the 1st dose and 84.8% for the booster dose. Conclusions. PCV13 was effective to reduce incidence of consolidated pneumonia and pleural effusion, among children less than 5 years of age in Concordia, Argentina. Vaccination is a very effective public health strategy for reducing vaccine preventable diseases, with impact on burden of disease and hospitalization.http://iris.paho.org/xmlui/handle/123456789/49588Pneumonia, pneumococcalStreptococcus pneumoniaepneumococcal vaccinesimmunization programsArgentina |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Raúl O. Ruvinsky Analía Rearte Judit Kupervaser Fernando Gentile Adriana Haidar Maria E. Cafure Maria Elisa Tito Federico Avaro Cristina Cortiana Hugo Cozzani Omar Véliz Sofia Fossati Mabel Regueira Carla Vizzotti |
spellingShingle |
Raúl O. Ruvinsky Analía Rearte Judit Kupervaser Fernando Gentile Adriana Haidar Maria E. Cafure Maria Elisa Tito Federico Avaro Cristina Cortiana Hugo Cozzani Omar Véliz Sofia Fossati Mabel Regueira Carla Vizzotti Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact Revista Panamericana de Salud Pública Pneumonia, pneumococcal Streptococcus pneumoniae pneumococcal vaccines immunization programs Argentina |
author_facet |
Raúl O. Ruvinsky Analía Rearte Judit Kupervaser Fernando Gentile Adriana Haidar Maria E. Cafure Maria Elisa Tito Federico Avaro Cristina Cortiana Hugo Cozzani Omar Véliz Sofia Fossati Mabel Regueira Carla Vizzotti |
author_sort |
Raúl O. Ruvinsky |
title |
Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact |
title_short |
Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact |
title_full |
Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact |
title_fullStr |
Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact |
title_full_unstemmed |
Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact |
title_sort |
community acquired pneumonia incidence among children less than 5 years of age in concordia, argentina: vaccination impact |
publisher |
Pan American Health Organization |
series |
Revista Panamericana de Salud Pública |
issn |
1020-4989 1680-5348 |
publishDate |
2018-11-01 |
description |
Objective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into the National Immunization Program of Argentina, and to describe variables associated with bacterial pneumonia and hospitalization. Methods. This was a prospective, population-based surveillance study of CAP incidence (ambulatory and hospitalized) among children less than 5 years of age in the Department of Concordia (Entre Rios, Argentina) from April 2014 – March 2016. The diagnosis of probable bacterial pneumonia (PBP) was determined following the standardized WHO protocol. Incidence during the post-vaccine introduction period was compared with the results from a previous study that used similar methodology for the pre-PCV13 introduction period from 2002 – 2005. Results. During the study period, 330 patients had a clinical diagnosis of CAP, of which 92 were PBP (6 with pleural effusion). S. pneumoniae was not isolated from any sample. No factors associated with PBP were found in multivariable analysis. The decrease in PBP and pleural effusion was significant in relation to the previous study: 63% (P < 0.0001) and 80.9% (P < 0.003), respectively. PCV13 uptake was 97.3% for the 1st dose and 84.8% for the booster dose. Conclusions. PCV13 was effective to reduce incidence of consolidated pneumonia and pleural effusion, among children less than 5 years of age in Concordia, Argentina. Vaccination is a very effective public health strategy for reducing vaccine preventable diseases, with impact on burden of disease and hospitalization. |
topic |
Pneumonia, pneumococcal Streptococcus pneumoniae pneumococcal vaccines immunization programs Argentina |
url |
http://iris.paho.org/xmlui/handle/123456789/49588 |
work_keys_str_mv |
AT rauloruvinsky communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT analiarearte communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT juditkupervaser communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT fernandogentile communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT adrianahaidar communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT mariaecafure communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT mariaelisatito communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT federicoavaro communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT cristinacortiana communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT hugocozzani communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT omarveliz communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT sofiafossati communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT mabelregueira communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact AT carlavizzotti communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact |
_version_ |
1725879266416001024 |